$REGN
REGENERON PHARMACEUTICALS, INC.

2014 Q3 Form 10-Q Financial Statement

#000153217614000046 Filed on November 04, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2013 Q3
Revenue $725.8M $597.0M
YoY Change 21.57% 39.59%
Cost Of Revenue $33.66M $28.25M
YoY Change 19.12% 40.25%
Gross Profit $692.1M $568.8M
YoY Change 21.69% 39.56%
Gross Profit Margin 95.36% 95.27%
Selling, General & Admin $144.0M $97.61M
YoY Change 47.53% 108.19%
% of Gross Profit 20.81% 17.16%
Research & Development $337.7M $224.0M
YoY Change 50.74% 41.54%
% of Gross Profit 48.8% 39.39%
Depreciation & Amortization $14.10M $10.80M
YoY Change 30.56% 14.89%
% of Gross Profit 2.04% 1.9%
Operating Expenses $481.7M $321.7M
YoY Change 49.77% 56.77%
Operating Profit $188.5M $236.8M
YoY Change -20.41% 17.02%
Interest Expense $9.232M $11.74M
YoY Change -21.34% 2.83%
% of Operating Profit 4.9% 4.96%
Other Income/Expense, Net -$6.641M -$11.12M
YoY Change -40.27% 2.04%
Pretax Income $181.8M $225.7M
YoY Change -19.43% 17.87%
Income Tax $98.45M $84.38M
% Of Pretax Income 54.14% 37.39%
Net Earnings $83.38M $141.3M
YoY Change -41.0% -26.2%
Net Earnings / Revenue 11.49% 23.67%
Basic Earnings Per Share $0.83 $1.44
Diluted Earnings Per Share $0.73 $1.25
COMMON SHARES
Basic Shares Outstanding 100.8M shares 98.23M shares
Diluted Shares Outstanding 117.4M shares 116.7M shares

Balance Sheet

Concept 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.042B $445.0M
YoY Change 134.16% 69.2%
Cash & Equivalents $646.6M $263.2M
Short-Term Investments $396.0M $182.0M
Other Short-Term Assets $139.0M $144.0M
YoY Change -3.47% 161.82%
Inventory $120.3M $63.29M
Prepaid Expenses
Receivables $673.9M $855.8M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.201B $1.634B
YoY Change 34.66% 72.27%
LONG-TERM ASSETS
Property, Plant & Equipment $819.0M $453.9M
YoY Change 80.43% 21.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $453.0M $330.0M
YoY Change 37.27% 5.43%
Other Assets $3.416M $4.409M
YoY Change -22.52% -75.94%
Total Long-Term Assets $1.539B $1.006B
YoY Change 52.93% 41.33%
TOTAL ASSETS
Total Short-Term Assets $2.201B $1.634B
Total Long-Term Assets $1.539B $1.006B
Total Assets $3.739B $2.640B
YoY Change 41.62% 59.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.00M $31.00M
YoY Change 51.61% 40.91%
Accrued Expenses $291.0M $188.0M
YoY Change 54.79% 84.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $410.2M $268.7M
YoY Change 52.65% 50.49%
LONG-TERM LIABILITIES
Long-Term Debt $564.0M $481.0M
YoY Change 17.26% 6.89%
Other Long-Term Liabilities $23.75M $10.57M
YoY Change 124.6% 51.32%
Total Long-Term Liabilities $23.75M $10.57M
YoY Change 124.6% 51.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $410.2M $268.7M
Total Long-Term Liabilities $23.75M $10.57M
Total Liabilities $1.188B $950.2M
YoY Change 24.98% 11.19%
SHAREHOLDERS EQUITY
Retained Earnings $145.2M -$189.5M
YoY Change -176.63% -80.81%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $43.85M
YoY Change
Treasury Stock Shares 521.9K shares
Shareholders Equity $2.552B $1.690B
YoY Change
Total Liabilities & Shareholders Equity $3.739B $2.640B
YoY Change 41.62% 59.0%

Cashflow Statement

Concept 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income $83.38M $141.3M
YoY Change -41.0% -26.2%
Depreciation, Depletion And Amortization $14.10M $10.80M
YoY Change 30.56% 14.89%
Cash From Operating Activities $164.4M $92.50M
YoY Change 77.73% -3954.17%
INVESTING ACTIVITIES
Capital Expenditures -$79.80M -$31.60M
YoY Change 152.53% 206.8%
Acquisitions
YoY Change
Other Investing Activities -$43.30M -$182.8M
YoY Change -76.31% 374.81%
Cash From Investing Activities -$123.0M -$214.4M
YoY Change -42.63% 339.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.200M 3.600M
YoY Change 44.44% -300.0%
NET CHANGE
Cash From Operating Activities 164.4M 92.50M
Cash From Investing Activities -123.0M -214.4M
Cash From Financing Activities 5.200M 3.600M
Net Change In Cash 46.60M -118.3M
YoY Change -139.39% 123.21%
FREE CASH FLOW
Cash From Operating Activities $164.4M $92.50M
Capital Expenditures -$79.80M -$31.60M
Free Cash Flow $244.2M $124.1M
YoY Change 96.78% 1470.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
63189000 USD
CY2014Q3 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
142619000 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
250896000 USD
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
337976000 USD
CY2014Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
47342000 USD
CY2013Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
61936000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
787071000 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
673915000 USD
CY2014Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
110720000 USD
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
104707000 USD
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26895000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1188000 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2423434000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2045857000 USD
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
343532000 USD
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
97840000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
166358000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
175866000 USD
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
156657000 USD
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-143041000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
144808000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
229692000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-20689000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
306976000 USD
CY2013Q4 us-gaap Assets
Assets
2951013000 USD
CY2014Q3 us-gaap Assets
Assets
3739419000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
1796934000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
2200512000 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
548267000 USD
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
849093000 USD
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
806130000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
548322000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
447000 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
1140000 USD
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
355738000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
239812000 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
1140000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
447000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
239812000 USD
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
355738000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
5124000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4138000 USD
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
496700000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
383410000 USD
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
0 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
1177000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
158376000 USD
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
287739000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
547101000 USD
CY2014Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
789563000 USD
CY2013Q3 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
500000 USD
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
1000000 USD
CY2013Q3 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0 USD
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
392000 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
44103000 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
1140000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
447000 USD
CY2014Q3 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
13500000 USD
CY2013Q3 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
0 USD
us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
14900000 USD
us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
0 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
535608000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
646554000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263211000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230276000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
32935000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
110946000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
141884000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
265981000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
325871000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
102352000 USD
CY2014Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
287950000 USD
CY2013Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
320315000 USD
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
33655000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
91073000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
83557000 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
28253000 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
360225000 USD
us-gaap Costs And Expenses
CostsAndExpenses
946378000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1426164000 USD
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
543069000 USD
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
521876 shares
CY2013Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
400000000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
82890000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-50466000 USD
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
57604000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
34185000 USD
CY2014Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
114339000 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
107677000 USD
CY2014Q3 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
49005000 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
44677000 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
231878000 USD
CY2014Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
263081000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38551000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29912000 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued a new standard related to revenue recognition, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. The new standard will be effective for annual and interim reporting periods beginning after December 15, 2016, and early adoption is not permitted. The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has not yet determined its method of transition and is evaluating the impact that this guidance will have on the Company's financial statements.</font></div></div>
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.37
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.95
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.10
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.571
CY2013Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.374
CY2014Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.547
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.364
us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.022
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.043
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
69429000 USD
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
75159000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
343532000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
97840000 USD
CY2013Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2014Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-10787000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
225684000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
176078000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
515207000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
554460000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
187651000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
84378000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
316562000 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
96358000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
76506000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
94894000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-27713000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
350809000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
29395000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20815000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
50917000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
36742000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28850000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3738000 USD
CY2013Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2885000 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2787000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2556000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2950000 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4033000 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4761000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4761000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9377000 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10379000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9515000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10220000 shares
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
4500000 USD
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
1000000 USD
us-gaap Interest Expense
InterestExpense
31022000 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
11736000 USD
us-gaap Interest Expense
InterestExpense
34776000 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
9232000 USD
CY2014Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2803000 USD
CY2013Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
4678000 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
13857000 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
CY2014Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11368000 USD
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
14352000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
70354000 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
120317000 USD
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9120000 USD
CY2014Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10170000 USD
CY2013Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
35868000 USD
CY2014Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
70965000 USD
us-gaap Inventory Write Down
InventoryWriteDown
4800000 USD
us-gaap Inventory Write Down
InventoryWriteDown
3500000 USD
CY2014Q3 us-gaap Inventory Write Down
InventoryWriteDown
1600000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
998937000 USD
CY2014Q3 us-gaap Liabilities
Liabilities
1187631000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3739419000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2951013000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
410200000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
298835000 USD
us-gaap Licenses Revenue
LicensesRevenue
23496000 USD
us-gaap Licenses Revenue
LicensesRevenue
20827000 USD
CY2014Q3 us-gaap Licenses Revenue
LicensesRevenue
8166000 USD
CY2013Q3 us-gaap Licenses Revenue
LicensesRevenue
6967000 USD
CY2014Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
395650000 USD
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
158376000 USD
CY2014Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
453443000 USD
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
389891000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43494000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-28425000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-477422000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-245507000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
306867000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
544874000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
79720000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
141306000 USD
us-gaap Net Income Loss
NetIncomeLoss
237898000 USD
us-gaap Net Income Loss
NetIncomeLoss
327556000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
82523000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
145984000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
237898000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
341413000 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11118000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32748000 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6641000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-36604000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
236802000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
547955000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
591064000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
182719000 USD
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
55683000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29022000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5327000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3416000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
28083000 USD
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
578000 USD
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22632000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1685000 USD
CY2014Q3 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
27814000 USD
CY2013Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
11014000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11330000 USD
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23747000 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
17316000 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
15629000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-12844000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-15710000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2028000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5205000 USD
CY2014Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2591000 USD
CY2013Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
618000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
143041000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
143041000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
166358000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
175866000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
478436000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
477312000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
215464000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
87347000 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
61732000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32952000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41718000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
80804000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
216478000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
319152000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
818967000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
526983000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
61125000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
810000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1625000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
337728000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
224045000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
591807000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
919608000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92692000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
145206000 USD
CY2014Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
132925000 USD
CY2013Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
134359000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
319161000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
406028000 USD
us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, prompt pay discounts, and other sales-related deductions. </font></div></div>
CY2014Q3 us-gaap Revenues
Revenues
725788000 USD
us-gaap Revenues
Revenues
2017228000 USD
us-gaap Revenues
Revenues
1494333000 USD
CY2013Q3 us-gaap Revenues
Revenues
597027000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1229244000 USD
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
367118000 USD
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
448844000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1019751000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
361012000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
97607000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
247330000 USD
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149748000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
143217000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
225784000 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
156373000 USD
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
0 USD
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
0 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79698000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42625000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
1952076000 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
2551788000 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
1690171000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1245385000 USD
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
CY2014Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
521892 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
521876 shares
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2014Q3 us-gaap Treasury Stock Value
TreasuryStockValue
43849000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 USD
CY2013Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
24601000 USD
CY2014Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
22795000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
78156000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
79962000 USD
CY2013Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
18487000 shares
CY2014Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16627000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
12878000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
17952000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115554000 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117423000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113203000 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116713000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100796000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98226000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97602000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100325000 shares
CY2014Q3 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
38600000 USD
CY2013Q3 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
18400000 USD
CY2013Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
16100000 USD
CY2012Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
8600000 USD
CY2014Q3 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
45384000 USD
CY2013Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
23654000 USD
CY2014Q3 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
114408000 USD
CY2013Q4 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
66855000 USD
CY2014Q3 regn Branded Prescription Drug Fee
BrandedPrescriptionDrugFee
40600000 USD
CY2013Q3 regn Costofmanufacturing
Costofmanufacturing
10320000 USD
regn Costofmanufacturing
Costofmanufacturing
54471000 USD
regn Costofmanufacturing
Costofmanufacturing
23684000 USD
CY2014Q3 regn Costofmanufacturing
Costofmanufacturing
21938000 USD
CY2014Q4 regn Debt Conversion
DebtConversion
160800000 USD
regn Debt Conversion
DebtConversion
61100000 USD
CY2014Q3 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
13368000 USD
CY2013Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
12815000 USD
CY2013Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
76522000 USD
CY2014Q3 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
75283000 USD
CY2013Q4 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
939000 USD
CY2014Q3 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
1252000 USD
CY2013Q4 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
184258000 USD
CY2014Q3 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
276112000 USD
regn Facilityleaseobligationrecognizedduringtheperiod
Facilityleaseobligationrecognizedduringtheperiod
92600000 USD
regn Facilityleaseobligationrecognizedduringtheperiod
Facilityleaseobligationrecognizedduringtheperiod
7700000 USD
CY2013Q3 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
462000 shares
CY2014Q3 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
430000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
415000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
413000 shares
regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentsmaybereceived200million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentsmaybereceived200million
200000000 USD
regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived
500000000 USD
regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million
600000000 USD
regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million
700000000 USD
CY2014Q3 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived800million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived800million
800000000 USD
CY2014Q3 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived900million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived900million
900000000 USD
regn Levelsoftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived1billion
Levelsoftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived1billion
1000000000 USD
CY2014Q2 regn Maximumnumberofsharesissuableuponexerciseofwarrants
Maximumnumberofsharesissuableuponexerciseofwarrants
4033324 shares
CY2014Q1 regn Maximumnumberofsharesissuableuponexerciseofwarrants
Maximumnumberofsharesissuableuponexerciseofwarrants
4760840 shares
regn Numberofsalesmilestonepaymentsthe Companyreceived
NumberofsalesmilestonepaymentstheCompanyreceived
5
CY2014Q3 regn Numberofsalesmilestonepaymentsthe Companyreceived
NumberofsalesmilestonepaymentstheCompanyreceived
2
CY2013Q3 regn Other Collaboration Revenue
OtherCollaborationRevenue
88583000 USD
CY2014Q3 regn Other Collaboration Revenue
OtherCollaborationRevenue
135853000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
134594000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
358460000 USD
regn Period For Achieving Sales Target For Milestone Payment Rolling Basis
PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
P12M
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000872589
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC

Files In Submission

Name View Source Status
0001532176-14-000046-index-headers.html Edgar Link pending
0001532176-14-000046-index.html Edgar Link pending
0001532176-14-000046.txt Edgar Link pending
0001532176-14-000046-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-093014x10q.htm Edgar Link pending
regn-20140930.xml Edgar Link completed
regn-20140930.xsd Edgar Link pending
regn-20140930_cal.xml Edgar Link unprocessable
regn-20140930_def.xml Edgar Link unprocessable
regn-20140930_lab.xml Edgar Link unprocessable
regn-20140930_pre.xml Edgar Link unprocessable
regn-ex_311x09302014x10q.htm Edgar Link pending
regn-ex_312x09302014x10q.htm Edgar Link pending
regn-ex_32x09302014x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending